S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
Log in
NASDAQ:PODD

Insulet Stock Forecast, Price & News

$259.10
-3.57 (-1.36 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$258.31
Now: $259.10
$270.27
50-Day Range
$254.65
MA: $276.48
$293.05
52-Week Range
$121.00
Now: $259.10
$298.43
Volume698,135 shs
Average Volume414,302 shs
Market Capitalization$17.08 billion
P/E Ratio588.88
Dividend YieldN/A
Beta0.76
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Its Omnipod System comprise two devices: a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, and its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, and the Middle East. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts.
Insulet logo

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:PODD
CUSIP45784P10
Phone978-600-7000
Employees1,350
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$738.20 million
Cash Flow$0.61 per share
Book Value$1.23 per share

Profitability

Net Income$11.60 million

Miscellaneous

Market Cap$17.08 billion
Next Earnings Date5/6/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.34 out of 5 stars

Medical Sector

664th out of 1,956 stocks

Surgical & Medical Instruments Industry

76th out of 165 stocks

Analyst Opinion: 2.1Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -
$259.10
-3.57 (-1.36 %)
(As of 02/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PODD News and Ratings via Email

Sign-up to receive the latest news and ratings for PODD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Insulet (NASDAQ:PODD) Frequently Asked Questions

Is Insulet a buy right now?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last twelve months. There are currently 1 sell rating, 13 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Insulet stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PODD, but not buy additional shares or sell existing shares.
View analyst ratings for Insulet
or view top-rated stocks.

What stocks does MarketBeat like better than Insulet?

Wall Street analysts have given Insulet a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Insulet wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Insulet's next earnings date?

Insulet is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Insulet
.

How were Insulet's earnings last quarter?

Insulet Co. (NASDAQ:PODD) released its quarterly earnings results on Monday, February, 22nd. The medical instruments supplier reported ($0.26) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.04) by $0.22. The medical instruments supplier had revenue of $246.10 million for the quarter, compared to the consensus estimate of $232.89 million. Insulet had a trailing twelve-month return on equity of 8.94% and a net margin of 3.33%. The firm's quarterly revenue was up 17.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.08 EPS.
View Insulet's earnings history
.

How has Insulet's stock been impacted by COVID-19?

Insulet's stock was trading at $172.11 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PODD stock has increased by 50.5% and is now trading at $259.10.
View which stocks have been most impacted by COVID-19
.

What guidance has Insulet issued on next quarter's earnings?

Insulet issued an update on its first quarter 2021 After-Hours earnings guidance on Tuesday, February, 23rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $245.52-253.44 million, compared to the consensus revenue estimate of $229.58 million.

What price target have analysts set for PODD?

20 brokers have issued 12 month target prices for Insulet's stock. Their forecasts range from $179.00 to $296.00. On average, they expect Insulet's stock price to reach $246.50 in the next twelve months. This suggests that the stock has a possible downside of 4.9%.
View analysts' price targets for Insulet
or view top-rated stocks among Wall Street analysts.

Who are Insulet's key executives?

Insulet's management team includes the following people:
  • Ms. Shacey Petrovic, Pres, CEO & Director (Age 47, Pay $1.9M)
  • Mr. Wayde D. McMillan, Exec. VP,CFO & Treasurer (Age 51, Pay $1.18M)
  • Mr. Charles Alpuche, Exec. VP & COO (Age 61, Pay $1.11M)
  • Mr. John Wodick Kapples, Sr. VP, Sec. & Gen. Counsel (Age 61, Pay $752.92k)
  • Mr. Bret Christensen, Exec. VP & Chief Commercial Officer (Age 49, Pay $975.77k)
  • Mr. Michael L. Levitz, Advisor (Age 47, Pay $1.06M)
  • Ms. Lauren Budden, VP, Chief Accounting Officer & Controller
  • Ms. Deborah R. Gordon CPA, VP of Investor Relations
  • Mr. Michael Spears, Sr. VP of Quality and Regulatory Affairs & Compliance (Age 56)
  • Angela Geryak Wiczek, Sr. Director of Corp. Communications

What is Shacey Petrovic's approval rating as Insulet's CEO?

61 employees have rated Insulet CEO Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among Insulet's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Insulet's key competitors?

What other stocks do shareholders of Insulet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Square (SQ), The Walt Disney (DIS), salesforce.com (CRM), Roku (ROKU) and The Trade Desk (TTD).

What is Insulet's stock symbol?

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Who are Insulet's major shareholders?

Insulet's stock is owned by a variety of retail and institutional investors. Top institutional investors include Primecap Management Co. CA (2.47%), Clearbridge Investments LLC (1.61%), William Blair Investment Management LLC (1.37%), Janus Henderson Group PLC (1.09%), Frontier Capital Management Co. LLC (0.99%) and Bank of New York Mellon Corp (0.79%). Company insiders that own Insulet stock include Aiman Abdel-Malek, Bret Christensen, Charles Alpuche, Corinne H Nevinny, David A Lemoine, David Colleran, Eric Benjamin, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic.
View institutional ownership trends for Insulet
.

Which institutional investors are selling Insulet stock?

PODD stock was sold by a variety of institutional investors in the last quarter, including Clearbridge Investments LLC, Frontier Capital Management Co. LLC, GW&K Investment Management LLC, Primecap Management Co. CA, Renaissance Technologies LLC, Kornitzer Capital Management Inc. KS, Columbus Circle Investors, and Victory Capital Management Inc.. Company insiders that have sold Insulet company stock in the last year include Bret Christensen, Charles Alpuche, Corinne H Nevinny, David A Lemoine, Eric Benjamin, John A Fallon, Michael P Spears, and Shacey Petrovic.
View insider buying and selling activity for Insulet
or view top insider-selling stocks.

Which institutional investors are buying Insulet stock?

PODD stock was purchased by a variety of institutional investors in the last quarter, including Viking Global Investors LP, Winslow Capital Management LLC, Janus Henderson Group PLC, Lord Abbett & CO. LLC, Sumitomo Mitsui Trust Holdings Inc., Alliancebernstein L.P., Nuveen Asset Management LLC, and Fisher Asset Management LLC.
View insider buying and selling activity for Insulet
or or view top insider-buying stocks.

How do I buy shares of Insulet?

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Insulet's stock price today?

One share of PODD stock can currently be purchased for approximately $259.10.

How much money does Insulet make?

Insulet has a market capitalization of $17.08 billion and generates $738.20 million in revenue each year. The medical instruments supplier earns $11.60 million in net income (profit) each year or $0.19 on an earnings per share basis.

How many employees does Insulet have?

Insulet employs 1,350 workers across the globe.

What is Insulet's official website?

The official website for Insulet is www.insulet.com.

Where are Insulet's headquarters?

Insulet is headquartered at 100 NAGOG PARK, ACTON MA, 01720.

How can I contact Insulet?

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]


This page was last updated on 2/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.